Aevi Genomic Medicine (GNMX) Shares Up 4.8%
Aevi Genomic Medicine Inc (NASDAQ:GNMX)’s share price shot up 4.8% on Monday . The company traded as high as $0.24 and last traded at $0.22. 14,142 shares traded hands during mid-day trading, a decline of 99% from the average session volume of 1,993,717 shares. The stock had previously closed at $0.21.
Several equities analysts recently weighed in on GNMX shares. ValuEngine lowered shares of Aevi Genomic Medicine from a “hold” rating to a “sell” rating in a report on Thursday, December 20th. JMP Securities lowered shares of Aevi Genomic Medicine from an “outperform” rating to a “market perform” rating in a report on Thursday, January 3rd.
The firm has a market cap of $14.83 million, a price-to-earnings ratio of -0.25 and a beta of 0.32.
About Aevi Genomic Medicine (NASDAQ:GNMX)
Aevi Genomic Medicine, Inc, a clinical stage biopharmaceutical company, researches and develops novel therapies for pediatric onset and life-altering diseases in the United States. The company's lead product candidates include AEVI-001, a glutamatergic neuromodulator, which has completed Phase II/III SAGA trial for the treatment of a genetically-defined subset of adolescent attention deficit hyperactivity disorder patients who have genetic mutations that disrupt the mGluR network resulting in glutamate imbalance; and AEVI-002, an anti-LIGHT monoclonal antibody that is in Phase Ib clinical trial for use in severe pediatric onset Crohn's disease.
Featured Story: Do back-end load funds outperform no-load funds?
Receive News & Ratings for Aevi Genomic Medicine Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aevi Genomic Medicine and related companies with MarketBeat.com's FREE daily email newsletter.